Composition for inhibiting skin photoaging and application thereof

Abstract

The invention relates to a composition for inhibiting skin photoaging and application thereof. The composition comprises a ginseng extract, an astragalus extract, sweet orange oil, shea butter and escin. The composition prepared by the invention can effectively improve skin injuries related to photoaging, including ultraviolet-induced epidermis thickening, collagen loss and skin inflammation, and promote collagen synthesis. The invention can be widely applied to the development of cosmetics, medical beauty products and medicines, and provides a new choice for preventing and treating skin aging.

Description

Technical Field

[0001] The invention belongs to the technical field of medicines and relates to a composition for inhibiting skin photoaging and application thereof. Background Art

[0002] With the development of society and the growing demand for beauty and skin care, skin aging, especially photoaging, has received widespread attention. Skin aging is divided into endogenous aging and exogenous aging. Photoaging is exogenous aging caused by ultraviolet radiation and is the main form of skin aging. Ultraviolet radiation is the main factor causing skin aging, which is also called photoaging. It includes dry skin, increased wrinkles, pigmentation, and may even induce skin cancer, which seriously affects people's health and beauty needs. Although there are a variety of anti-photoaging cosmetics and treatments on the market, their effects are uneven, and some products may contain chemical ingredients, which may cause irritation or side effects to the skin if used for a long time. In addition, existing anti-photoaging products often only focus on a single improvement effect, such as improving skin moisture or elasticity, but ignore that photoaging is a complex process involving many factors, including collagen loss, oxidative stress, inflammatory response, cell apoptosis, etc.

[0003] Existing studies have shown that ultraviolet radiation can cause a variety of biological changes in the skin, such as inducing the production of reactive oxygen species and lipid peroxide malondialdehyde, inducing the expression of metalloproteinases, and other pathways that induce skin photoaging. Ultraviolet rays can also affect the expression of micro RNA in skin cells, thereby affecting gene expression and cell function, leading to skin aging. In addition, ultraviolet irradiation can also lead to the degradation of collagen and elastin in the skin, affecting the structure and function of the extracellular matrix, thereby promoting the process of skin photoaging. However, current treatments often focus on a single biological pathway or a single skin layer, ignoring that the skin is a complex organ and the effects of photoaging are multifaceted. For example, existing treatments may only focus on reducing ultraviolet-induced epidermal thickening or collagen loss, without considering promoting the activity of antioxidant enzymes in skin tissue, or reducing skin inflammation by reducing the expression of inflammatory factors; they also often ignore the importance of promoting skin cell repair and collagen synthesis, as well as inhibiting ultraviolet-induced cell oxidative stress damage and apoptosis.

[0004] Therefore, it is an urgent need to develop a novel composition that can comprehensively improve the symptoms of photoaging, which can not only reduce UV-induced skin damage, but also promote the repair of skin cells and the synthesis of collagen, while inhibiting oxidative stress damage and apoptosis. The present invention is based on this background and aims to provide a new composition and its application in cosmetics to comprehensively improve the symptoms of photoaging and improve the health and beauty of the skin. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a composition for inhibiting skin photoaging and its application.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a composition for inhibiting skin photoaging, the composition comprising ginseng extract, astragalus extract, sweet orange oil, shea butter and aescin.

[0008] Skin photoaging includes one or more phenomena such as changes in skin structure and function, rough and dry skin, pigmentation, decreased skin elasticity, skin pathological changes, skin cancer, etc. The composition for inhibiting skin photoaging prepared by the present invention can effectively improve skin damage related to photoaging, including inhibiting tyrosinase activity and effectively removing ABTS + Free radicals, reduce cell damage caused by UV damage, enhance cell proliferation activity, reduce the level of ROS in cells, reduce oxidative stress, protect cells from damage, reduce UV-induced epidermal thickening, collagen loss and skin inflammation, promote collagen synthesis, and ginseng extract, astragalus extract, sweet orange oil, shea butter and aescin have a certain synergistic effect on the above effects.

[0009] Preferably, the composition comprises, by mass, 5-8 parts of ginseng extract, 5-8 parts of astragalus extract, 0.3-1 parts of sweet orange oil, 15-20 parts of shea butter and 3.7-7 parts of aescin.

[0010] The mass proportion of ginseng extract can be 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, etc. The mass proportion of astragalus extract can be 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, etc. The mass proportion of sweet orange oil can be 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 parts, etc. The mass proportion of shea butter can be 15 parts, 15 .5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5 parts, 19 parts, 19.5 parts, 20 parts, etc. The mass parts of aescin can be selected as 3.7 parts, 4 parts, 4.2 parts, 4.5 parts, 4.8 parts, 5 parts, 5.2 parts, 5.5 parts, 5.8 parts, 6 parts, 6.2 parts, 6.5 parts, 6.8 parts, 7 parts, etc. Other specific points within the above numerical range can be selected, so they will not be described one by one here.

[0011] Preferably, the composition further comprises an extract of Atractylodes macrocephala, an extract of Ampelopsis pilosula, an extract of Bletilla striata, an extract of Paeonia lactiflora and an extract of Poria cocos.

[0012] When Atractylodes macrocephala extract, Bletilla striata extract, Bletilla striata extract, Paeonia lactiflora extract and Poria cocos extract are additionally added to the composition, the effect is better.

[0013] Preferably, the composition further comprises, by mass, 15-20 parts of Atractylodes macrocephala extract, 15-20 parts of Ampelopsis pilosula extract, 6-10 parts of Bletilla striata extract, 15-20 parts of Paeonia lactiflora extract and 5-8 parts of Poria cocos extract.

[0014] The mass proportion of Atractylodes macrocephala extract can be selected from 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5 parts, 19 parts, 19.5 parts, 20 parts, etc.; the mass proportion of Bletilla striata extract can be selected from 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5 parts, 19 parts, 19.5 parts, 20 parts, etc.; the mass proportion of Bletilla striata extract can be selected from 6 parts, 6.5 parts, 7 parts, 7.5 parts The mass parts of peony extract can be selected from 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5 parts, 19 parts, 19.5 parts, 20 parts, etc. The mass parts of Poria cocos extract can be selected from 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, etc. Other specific point values ​​within the above numerical range can be selected, so they will not be listed here one by one.

[0015] Preferably, the oil is prepared by a method comprising the following steps: physically pressing the raw materials to obtain the oil.

[0016] Preferably, the oils and fats include sweet orange oil and shea butter.

[0017] Preferably, the extract is independently prepared by a method comprising the following steps: mixing the preparation raw material with water at a solid-liquid ratio of 1 g: (10-15) mL, decocting for 50-70 min, filtering, concentrating the filtrate and drying to obtain the extract.

[0018] The specific point values ​​in (10-15) can be selected as 10, 11, 12, 13, 14, 15, etc., and the time can be selected as 50 min, 52 min, 55 min, 58 min, 60 min, 62 min, 65 min, 68 min, 70 min, etc. Other specific point values ​​within the above numerical range can be selected, and they will not be listed here one by one.

[0019] In the present invention, the extracts are all prepared by the above method, which can be prepared by mixing the raw materials and then boiling and drying them, or by boiling and drying them separately and then physically mixing them.

[0020] In a second aspect, the present invention provides a use of the composition for inhibiting skin photoaging according to the first aspect in preparing a product for preventing and / or treating skin photoaging.

[0021] Preferably, the product comprises a cosmetic or a medicine.

[0022] The invention can be widely applied to the development of cosmetics, medical cosmetic products and medicines, and provides a new option for preventing and treating skin aging.

[0023] Preferably, the mass percentage of the composition for inhibiting skin photoaging in the product is 0.01-10%, for example, 0.01%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, etc. Other specific points within the above numerical range can be selected and will not be described here one by one.

[0024] In a third aspect, the present invention provides a cream for inhibiting skin photoaging, the cream comprising the composition described in the first aspect and acceptable excipients.

[0025] Preferably, the cream comprises, by mass percentage, 0.01-10% of the composition for inhibiting skin photoaging and 90-99.99% of acceptable excipients.

[0026] The mass percentage of the composition can be selected from 0.01%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10% and the like; the mass percentage of the auxiliary material can be selected from 90%, 90.5%, 91%, 91.5%, 92%, 92.5%, 93%, 93.5%, 94%, 94.5%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.99% and the like; other specific point values ​​within the above numerical range can be selected, which will not be described one by one here.

[0027] Preferably, the acceptable excipients include any one of solvents, oils, thickeners, humectants or preservatives, or a combination of at least two of them.

[0028] Preferably, the solvent comprises water.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] (1) The composition provided by the present invention has a good effect of scavenging oxidative free radicals.

[0031] (2) The composition provided by the present invention has a good effect of inhibiting tyrosinase.

[0032] (3) The composition provided by the present invention is non-cytotoxic and has good safety.

[0033] (4) The composition provided by the present invention has a significant effect of inhibiting the production of reactive oxygen species and enhancing cell proliferation activity in skin cells damaged by ultraviolet rays.

[0034] (5) The safety and non-irritation of the composition cream provided by the present invention have been verified by the chicken embryo chorioallantoic membrane test, thus ensuring the mildness and applicability of the final product.

[0035] (6) The composition cream provided by the present invention can reduce skin edema and the formation of erythema or eschar in mice after ultraviolet light exposure, improve pigmentation, epidermal thickening and collagen loss, promote the activity of antioxidant enzymes in skin tissue, and reduce skin inflammation by reducing the expression of IL-1β, IL-6 and TNF-α.

[0036] (7) The composition provided by the present invention is easy to add and prepare various preparations, can be produced on a large scale, and can be used to prepare cosmetics, medical beauty products or medicines to help inhibit skin photoaging. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 It is the safety test result.

[0038] Figure 2A This is a graph showing the effects of different treatments on skin damage on the back of mice after ultraviolet irradiation.

[0039] Figure 2B This is a statistical chart showing the effects of different treatments on skin damage on the back of mice after ultraviolet irradiation.

[0040] Figure 3 This is the result of H&E staining of the back skin of light-damaged mice.

[0041] Figure 4 The invention discloses the effect of a cream containing the composition on the collagen content in the back skin of ultraviolet-irradiated mice.

[0042] Figure 5A The present invention is the result of the effect of the cream containing the composition on the IL-1β content in the back skin of ultraviolet-irradiated mice.

[0043] Figure 5B The present invention is the result of the effect of the cream containing the composition on the IL-6 content in the back skin of ultraviolet-irradiated mice.

[0044] Figure 5CThe invention discloses the effect of the cream containing the composition on the TNF-α content in the back skin of ultraviolet-irradiated mice. DETAILED DESCRIPTION

[0045] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.

[0046] The sources of the functional ingredients contained in the products involved in the following embodiments and comparative examples are as follows (only the functional ingredients are reflected, and the necessary auxiliary ingredients contained in other commercially available raw materials are not repeated):

[0047] The emulsifier was a product purchased from Nikko Chemical Trading (Shanghai) Co., Ltd. under the trade name NIKKOL LECINOL S-10;

[0048] Sodium polyacrylate was purchased from BASF (China) Co., Ltd. under the trade name Cosmedia® SP;

[0049] Carbomer sodium was purchased from SUMITOMO SEIKA CHEMICALS CO., LTD. under the trade name AQUPEC MGN40R;

[0050] Jojoba oil was purchased from Vantage Specialty Chemicals, Inc. under the trade name DW Jojoba Golden;

[0051] The preparation method of each extract in the present invention is: mixing the preparation raw material and water at a solid-liquid ratio of 1 g:12 mL, decocting for 60 min, filtering, concentrating the filtrate and drying to obtain the extract.

[0052] The preparation method of the sweet orange oil and shea butter of the present invention comprises the following steps: physically squeezing the raw materials to obtain the sweet orange oil and shea butter.

[0053] Example 1

[0054] This embodiment provides a composition for inhibiting skin photoaging, which comprises, by mass, 6 parts of ginseng extract, 6.5 parts of astragalus extract, 0.5 parts of sweet orange oil, 18 parts of shea butter and 5 parts of aescin.

[0055] The preparation method thereof is as follows: mixing the preparation raw materials to obtain the product.

[0056] Example 2

[0057] This embodiment provides a composition for inhibiting skin photoaging, which comprises, by mass, 5 parts of ginseng extract, 8 parts of astragalus extract, 0.3 parts of sweet orange oil, 15 parts of shea butter and 7 parts of aescin.

[0058] The preparation method is similar to that of Example 1.

[0059] Example 3

[0060] This embodiment provides a composition for inhibiting skin photoaging, wherein the composition comprises, by mass, 8 parts of ginseng extract, 5 parts of astragalus extract, 1 part of sweet orange oil, 20 parts of shea butter, and 3.7 parts of aescin.

[0061] The preparation method is similar to that of Example 1.

[0062] Example 4

[0063] The present embodiment provides a composition for inhibiting skin photoaging, which comprises, by mass, 6 parts of ginseng extract, 6.5 parts of astragalus extract, 0.5 parts of sweet orange oil, 18 parts of shea butter and 5 parts of aescin, 18 parts of atractylodes extract, 18 parts of white ampel extract, 8 parts of bletilla striata extract, 18 parts of peony extract, and 6 parts of Poria extract.

[0064] The preparation method is similar to that of Example 1.

[0065] Example 5

[0066] The present embodiment provides a composition for inhibiting skin photoaging, which comprises, by mass, 5 parts of ginseng extract, 8 parts of astragalus extract, 0.3 parts of sweet orange oil, 15 parts of shea butter and 7 parts of aescin, 15 parts of atractylodes extract, 20 parts of ampelopsis extract, 6 parts of bletilla striata extract, 15 parts of peony extract, and 8 parts of Poria extract.

[0067] The preparation method is similar to that of Example 1.

[0068] Example 6

[0069] The present embodiment provides a composition for inhibiting skin photoaging. The composition includes, by mass, 8 parts of ginseng extract, 5 parts of astragalus extract, 1 part of sweet orange oil, 20 parts of shea butter and 3.7 parts of aescin, 20 parts of atractylodes extract, 15 parts of white ampel extract, 10 parts of bletilla striata extract, 20 parts of peony extract, and 5 parts of Poria extract.

[0070] The preparation method is similar to that of Example 1.

[0071] Comparative Example 1

[0072] This comparative example provides a composition for inhibiting skin photoaging, which is different from Example 1 only in that it does not contain ginseng extract, and its reduced mass is proportionally distributed to the mass of astragalus extract, sweet orange oil, shea butter and aescin.

[0073] The preparation method is similar to that of Example 1.

[0074] Comparative Example 2

[0075] This comparative example provides a composition for inhibiting skin photoaging, which is different from Example 1 only in that it does not contain the astragalus extract, and its reduced mass is proportionally distributed to the masses of the ginseng extract, sweet orange oil, shea butter and aescin.

[0076] The preparation method is similar to that of Example 1.

[0077] Comparative Example 3

[0078] This comparative example provides a composition for inhibiting skin photoaging, which is different from Example 1 only in that it does not contain sweet orange oil, and its reduced mass is proportionally distributed to the masses of ginseng extract, astragalus extract, shea butter and aescin.

[0079] The preparation method is similar to that of Example 1.

[0080] Comparative Example 4

[0081] This comparative example provides a composition for inhibiting skin photoaging, which is different from Example 1 only in that it does not contain shea butter, and its reduced mass is proportionally distributed to the masses of ginseng extract, astragalus extract, sweet orange oil and aescin.

[0082] The preparation method is similar to that of Example 1.

[0083] Comparative Example 5

[0084] This comparative example provides a composition for inhibiting skin photoaging, which is different from Example 1 only in that it does not contain aescin, and its reduced mass is proportionally distributed to the masses of ginseng extract, astragalus extract, sweet orange oil and shea butter.

[0085] The preparation method is similar to that of Example 1.

[0086] Application Example 1

[0087] This application example provides a cream for inhibiting skin photoaging, and the composition of the cream is: 3.3 parts of the composition of Example 1, 72.9 parts of water, 8 parts of glycerol, 5 parts of 1,3-butylene glycol, 0.7 parts of emulsifier, 7.5 parts of jojoba oil, 0.8 parts of sodium polyacrylate, 0.8 parts of sodium carbomer, 0.5 parts of 1,2-hexanediol, and 0.5 parts of p-hydroxyacetophenone.

[0088] Its preparation method is:

[0089] (1) Sodium polyacrylate, sodium carbomer, glycerin, 1,3-butylene glycol, 1,2-hexanediol, p-hydroxyacetophenone and an emulsifier are dispersed in water, mixed with the composition, and heated to 85° C. with stirring to completely melt the mixture.

[0090] (2) Mix jojoba oil and the product of step (1), homogenize, and cool to room temperature to obtain the product.

[0091] Comparative application example 1

[0092] This comparative application example provides a cream, which differs from application example 1 only in that it does not contain the composition of example 1, and other ingredients and contents remain unchanged.

[0093] The preparation method refers to Application Example 1.

[0094] Test Example 1

[0095] ABTS + Free radical scavenging rate test

[0096] ABTS (2,2'-Azino-bis-3-ethylbenzothiazoline-6-sulfonic acid) reacts with K2S2O8 to generate a stable cationic radical ABTS + , the free radical is green and has a maximum absorption peak at 734 nm. When the free radical scavenger is present, ABTS + Free radicals will be consumed and the absorbance will decrease, so the ability of the sample to scavenge free radicals can be evaluated by measuring the change in absorbance.

[0097] Test method: Mix 7.4 mM ABTS and 2.6 mM K2S2O8 and keep them in dark place for 12 h to obtain ABTS stock solution. Dilute the ABTS stock solution with PBS buffer until the absorbance at 734 nm is 0.7±0.02 to obtain ABTS working solution.

[0098] Take 0.2 mL of working solution and mix it with 10 μL of test sample or PBS solution, keep it at room temperature away from light for 6 min, and measure the absorbance at 734 nm using a multifunctional microplate reader.

[0099] The concentration of the test samples was 10 mg / mL.

[0100] ABTS + Free radical scavenging rate (%) = (A0-A) / (A0) × 100%

[0101] Where A0 is the absorbance of the PBS control solution and A is the absorbance in the presence of the test sample.

[0102] The results are shown in Table 1.

[0103] Table 1

[0104]

[0105] From the data in Table 1, it can be seen that the composition of the present invention has a higher ABTS + Free radical scavenging rate and antioxidant effect are good, and ginseng extract, astragalus extract, sweet orange oil, shea butter and aescin have a certain synergistic effect on the above effects.

[0106] Test Example 2

[0107] Tyrosinase inhibitory activity test

[0108] The color of human skin is related to the type and amount of pigments in the skin, and melanin has the greatest impact on skin color. Melanin is formed in melanocytes at the base of the epidermis. The process is that tyrosine in melanocytes generates dopa and dopaquinone under the action of tyrosinase and finally forms melanin. Tyrosinase is the key enzyme in melanogenesis, which controls the formation process of melanin. The strength of tyrosinase inhibition is the main indicator for evaluating whitening and anti-freckle cosmetics.

[0109] Weigh 13.59 mg of tyrosine powder and dissolve it in 15 mL PBS (pH=6.8), and ultrasonicate for 30 min to obtain a 5 mmol / L tyrosine solution; accurately weigh 50 KU of tyrosinase powder, add PBS to a 250 mL brown volumetric flask to obtain a tyrosinase solution with an activity of 200 U / mL, add 40 μL PBS phosphate buffer (pH=6.8), 40 μL of test samples of different concentrations (0.8 mg / mL, 2.4 mg / mL, 7 mg / mL), and 80 μL of tyrosine solution to a 96-well plate, mix well, incubate at 37°C for 20 min, add 40 μL of tyrosinase solution, incubate at 37°C for 15 min, and measure the absorbance of the sample group at a wavelength of 475 nm in an ELISA reader. The tyrosinase inhibition rate was calculated according to the following formula:

[0110] Tyrosinase inhibition rate (%) = [(A0-A1)-(A2-A3)] / (A0-A1)×100%

[0111] A0 is the absorbance of the control group without test sample; A1 is the absorbance of the mixed solution without test sample and tyrosinase; A2 is the absorbance of the mixed solution with test sample and tyrosinase; A3 is the absorbance of the mixed solution with test sample and without tyrosinase.

[0112] The results are shown in Table 2.

[0113] Table 2

[0114]

[0115] It can be seen from the data in Table 2 that the composition of the present invention has a higher tyrosinase inhibition rate and a good whitening effect, and the ginseng extract, astragalus extract, sweet orange oil, shea butter and aescin have a certain synergistic effect on the above effects.

[0116] Test Example 3

[0117] Evaluation of cytotoxicity against HaCaT cells

[0118] When the HaCaT cells (human immortalized epidermal keratinocytes, purchased from Wuhan Punosai Biotechnology Co., Ltd.) to be cultured grow to 80% density, 100 μL of cell suspension is taken after digestion and inoculated into a 96-well culture plate. After the cells adhere to the wall, different concentrations of the composition (0.8 mg / mL, 2.4 mg / mL, 7 mg / mL) are added to the 96-well plate and incubated for 24 h. After the end, 10 μL of CCK-8 solution (purchased from MedChemexpress Biotechnology Company) is added to each well, incubated at 37°C in the dark for 40 min, and the absorbance of each well is measured at 450 nm with an enzyme reader. The results are shown in Table 3, indicating that the composition in each group is safe and has no toxic side effects on cells.

[0119] Cell viability (%) = A1 / A0 × 100%

[0120] A0 is the absorbance of the control group without test sample, and A1 is the absorbance of the test sample group.

[0121] Table 3

[0122]

[0123] It can be seen from the results in Table 3 that the composition prepared by the present invention has no cytotoxicity and is highly safe.

[0124] Test Example 4

[0125] Effects of UV-irradiated HaCaT cells on proliferation and ROS clearance

[0126] The HaCaT cell suspension was inoculated into a 96-well plate, and after the cells adhered to the wall, the cells were treated with different concentrations of the composition (0.8 mg / mL, 2.4 mg / mL, and 7 mg / mL) for 8 h. The cell culture plate was then placed under a UV crosslinker to construct a UV damage model. 2The light-induced irradiation was carried out for 30 min under the conditions. After irradiation, the ROS level in each group of cells was measured using a ROS detection kit (purchased from Beijing Solebow Technology Co., Ltd.). In addition, in order to determine the effect on cell proliferation, the cells were cultured for 8 h after light damage modeling, and the effect of the composition on HaCaT cell proliferation was detected according to the instructions of the CCK-8 kit. The results of ROS fluorescence intensity are shown in Table 4, and the results of cell viability are shown in Table 5.

[0127] Table 4

[0128]

[0129] Table 5

[0130]

[0131] It can be seen from Tables 4 and 5 that the composition of the present invention has good antioxidant capacity and strong ROS scavenging ability, and the ginseng extract, astragalus extract, sweet orange oil, shea butter and aescin have a certain synergistic effect on the above effects.

[0132] Test Example 5

[0133] Safety Experiment

[0134] The composition of the present invention adopts water decoction extraction in the preparation process, which retains the active ingredients of the medicinal materials to the greatest extent and reduces the impurities that may cause skin irritation. In addition, its safety and non-irritation are verified by chicken embryo chorioallantoic membrane test and in vitro cell experiment, ensuring the mildness and applicability of the final product.

[0135] Thirty healthy white Laihang chicken embryos were fertilized and incubated until the 8th day. The eggs were candled and checked with an egg candling device. Unfertilized and inactive embryos were discarded. The embryos with well-developed blood vessels were selected and the position of the air chamber was marked on the eggshell surface. The eggs were divided into a negative control group (0.9% saline), a positive control group (0.1 mol / L sodium hydroxide) and a test group (combination cream group). The experiment started on the 9th day. The eggshell part of the air chamber was carefully peeled off with dental curved forceps, and a few drops of saline were dripped on the surface of the eggshell membrane to fully wet it. After pouring it out, the eggshell membrane was carefully removed with forceps to ensure that the exposed chorioallantoic membrane was intact and not damaged. Both the negative control and the positive control were transparent liquids. The reaction time method was used. 0.3 mL of the control sample was directly dripped on the surface of the chorioallantoic membrane (CAM) of the chicken embryo. The CAM reaction was observed and the time of each toxic effect within 5 minutes after the action was recorded. The test sample was an opaque cream. The endpoint evaluation method was used. 0.3 g of the test substance was directly applied to the CAM to ensure that the coverage area reached at least 50%. After 3 min of exposure, the CAM surface was gently rinsed with physiological saline within 30 s. The liquid was poured out and the degree of change of each toxic effect was immediately observed under a stereomicroscope and a score (ES) was given. After the 3 min exposure was completed, photos were taken immediately at the beginning of the observation.

[0136] The results are determined according to the industry standard SN / T 2329-2009 "Chicken Embryo Chorioallantoic Membrane Eye Irritation Test", and the result calculation formula is as follows:

[0137] Reaction time method:

[0138]

[0139] Wherein: sec H (bleeding time): the average time from the onset of bleeding observed on the CAM, in seconds (s); sec L (vascular lysis time): the average time from the onset of vascular lysis observed on the CAM, in seconds (s); sec C (coagulation time): the average time from the onset of coagulation observed on the CAM, in seconds (s).

[0140] Determination method: Reaction time method: IS < 1 is non-irritating, 1 ≤ IS < 5 is mildly irritating, 5 ≤ IS < 9 is moderately irritating, and IS ≥ 10 is strongly irritating / corrosive.

[0141] End point evaluation method:

[0142]

[0143] Judgment method: ES≤4 is mild without irritation, 4<ES≤12 is mild irritation, and ES≥16 is severe irritation.

[0144] Table 6

[0145]

[0146] The results are as follows Figure 1 As shown in Table 6, under the test conditions, the sample composition cream is mild and non-irritating.

[0147] Test Example 6

[0148] Inhibitory effect on UV-induced photoaging model of mouse skin

[0149] A 20 g male ICR mouse (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) was taken and depilated on its back with a depilatory cream. The depilatory area was about 2 cm × 2 cm. The mice were randomly divided into a model group (comparative application example 1) and a combination cream group (application example 1), with 10 mice in each group. An LED UVB lamp was placed vertically above the back of the mouse. After preheating for 5 min, a total irradiation of 500 mJ / cm 2 , irradiation continued for 5 min, after irradiation, each group applied the corresponding cream to the injured area, irradiation and medication continued for 14 days, and the skin condition was recorded. In order to observe the skin histological differences of mice before and after treatment with the composition, H&E staining was performed on the skin sections of UV-irradiated mice on the 14th day, and the collagen level and the content of inflammatory factors IL-1β, IL-6 and TNF-α in the aged skin tissue were determined.

[0150] The results are as follows Figure 2A and Figure 2B As shown in the figure, after ultraviolet irradiation, the model group gradually showed damage conditions such as dry skin, erythema or eschar, rough wrinkles and epidermal thickening. On the 14th day, the skin at the irradiated site showed sagging, large-area erythema, pigmentation, eschar, rough wrinkles and other phenomena. Compared with the model group, the skin damage on the back of the mice in the combination group was significantly improved, including sagging, roughness, erythema and scab. The statistical results of the percentage of skin damage showed that the proportion of damaged skin area in the combination group was significantly reduced compared with the model group. Pathological staining of back skin tissue is shown in Figure 1. Figure 3 As shown, the epidermis of mice in the photoaging model group was thickened, the fibers in the dermis were reduced, broken, and arranged in a disordered manner, and there was a large infiltration of inflammatory cells. These changes indicate that ultraviolet irradiation causes the destruction of skin collagen and elastic fibers, which is an important feature of skin photoaging. Compared with the model, the combination group increased the thickness of the epidermis and improved the arrangement of elastic fibers and collagen fibers in the dermis to play a role in repairing photodamaged skin.

[0151] The collagen content of the aged skin of mice was measured. Figure 4 As shown, compared with the model group, the content of collagen in the skin of the combination group increased, which shows that the combination can reduce the loss of collagen and thus fight against skin aging.

[0152] The levels of inflammatory factors IL-1β, IL-6 and TNF-α cytokines in aged skin were detected. Figure 5A , Figure 5B and Figure 5C As shown, the level of inflammatory factors in the composition treatment group was significantly reduced, thereby alleviating the damage to the skin caused by inflammatory response and improving the aging state of the skin.

[0153] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate a composition for inhibiting skin photoaging and its application, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0154] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0155] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A composition for inhibiting skin photoaging, characterized in that: The composition includes ginseng extract, astragalus extract, sweet orange oil, shea butter and aescin.

2. The composition for inhibiting skin photoaging according to claim 1, characterized in that: The composition comprises 5-8 parts of ginseng extract, 5-8 parts of astragalus extract, 0.3-1 parts of sweet orange oil, 15-20 parts of shea butter and 3.7-7 parts of aescin by weight.

3. The composition for inhibiting skin photoaging according to claim 1, characterized in that: The composition further comprises an extract of Atractylodes macrocephala, an extract of Ampelopsis radix, an extract of Bletilla striata, an extract of Paeonia lactiflora and an extract of Poria cocos.

4. The composition for inhibiting skin photoaging according to claim 3, characterized in that: The composition further comprises, by weight, 15-20 parts of Atractylodes macrocephala extract, 15-20 parts of Ampelopsis pilosula extract, 6-10 parts of Bletilla striata extract, 15-20 parts of Paeonia lactiflora extract and 5-8 parts of Poria cocos extract.

5. Use of the composition for inhibiting skin photoaging according to any one of claims 1 to 4 in the preparation of a product for preventing and / or treating skin photoaging.

6. The use according to claim 5, characterized in that: The product includes a cosmetic or a medicine.

7. The use according to claim 5, characterized in that: The mass percentage of the composition for inhibiting skin photoaging in the product is 0.01-10%.

8. A cream for inhibiting skin photoaging, characterized in that: The cream comprises the composition according to any one of claims 1 to 4 and acceptable excipients.

9. The cream for inhibiting skin photoaging according to claim 8, characterized in that: The cream comprises, by mass percentage, 0.01-10% of a composition for inhibiting skin photoaging and 90-99.99% of acceptable auxiliary materials.

10. The cream for inhibiting skin photoaging according to claim 8, characterized in that: The acceptable excipients include any one of solvents, oils, thickeners, humectants or preservatives, or a combination of at least two of them.

Images